Search

Your search keyword '"Nosaka, Kazumasa"' showing total 37 results
Start Over Author "Nosaka, Kazumasa"
37 results on '"Nosaka, Kazumasa"'

5. Prognostic Impact of the Early Use of Tolvaptan in Elderly Patients with Acute Decompensated Heart Failure

Author

Okada, Tomoaki, primary, Miyoshi, Toru, additional, Oka, Akihiro, additional, Tsushima, Ryu, additional, Sudo, Yuya, additional, Seiyama, Kosuke, additional, Takagi, Wataru, additional, Kawaguchi, Tomohiro, additional, Ozaki, Masatomo, additional, Sogo, Masahiro, additional, Ugawa, Satoko, additional, Nosaka, Kazumasa, additional, Takahashi, Masahiko, additional, Okawa, Keisuke, additional, and Doi, Masayuki, additional

Published
2023
Full Text
View/download PDF

11. Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial

Author

Okada, Tomoaki, Miyoshi, Toru, Doi, Masayuki, Nosaka, Kazumasa, Tsushima, Ryu, Ugawa, Satoko, Takagi, Wataru, Sogo, Masahiro, Takahashi, Masahiko, Ito, Hiroshi, Okada, Tomoaki, Miyoshi, Toru, Doi, Masayuki, Nosaka, Kazumasa, Tsushima, Ryu, Ugawa, Satoko, Takagi, Wataru, Sogo, Masahiro, Takahashi, Masahiko, and Ito, Hiroshi

Abstract

Elevated circulating lipoprotein(a) levels are associated with an increased risk of cardiovascular events. We reported that early initiation of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in addition to a statin substantially reduced the lipoprotein(a) levels in patients with acute myocardial infarction (AMI) after primary percutaneous coronary intervention (PCI). This sub-analysis sought to investigate the effect of evolocumab on lipoprotein(a) based on baseline lipoprotein(a) levels and characteristics. This study was a prespecified analysis of a randomized controlled trial that enrolled 102 patients who underwent primary PCI for AMI. Patients received pitavastatin (2 mg/day) alone or pitavastatin and evolocumab 140 mg subcutaneously within 24 h and 2 weeks after the index PCI. The evolocumab group showed significantly suppressed lipoprotein(a) levels in patients with baseline lipoprotein(a) levels of <= 10 mg/dL, 10 < lipoprotein(a) <= 20 mg/dL, and >20 mg/dL compared with the control group, as well as similar reductions in lipoprotein(a) levels in all patient subgroups. Among these subgroups, evolocumab tended to show more favorable effects in patients with diabetes mellitus. In AMI patients, early initiation of evolocumab therapy within 24 h of primary PCI suppressed the increase in lipoprotein(a) levels within 4 weeks, regardless of baseline levels and characteristics.

Published
2022

12. Lotus root-like appearance in the left anterior descending artery treated with a drug-coated balloon angioplasty

Author

Takagi, Wataru, Okada, Tomoaki, Nosaka, Kazumasa, Miyoshi, Toru, Doi, Masayuki, Takagi, Wataru, Okada, Tomoaki, Nosaka, Kazumasa, Miyoshi, Toru, and Doi, Masayuki

Abstract

A lotus root-like appearance of the coronary artery diagnosed by optical coherence tomography (OCT) is characterized by old coronary thrombi that form small lumen channels. Herein, serial OCT images of a left anterior descending artery with a lotus root-like appearance, treated with drug-coated balloon angioplasty are described.

Published
2022

13. Fulminant myocarditis after the second dose of COVID-19 mRNA vaccination

Author

Oka, Akihiro, Sudo, Yuya, Miyoshi, Toru, Ozaki, Masatomo, Kimura, Yuta, Takagi, Wataru, Ugawa, Satoko, Okada, Tomoaki, Nosaka, Kazumasa, Doi, Masayuki, Oka, Akihiro, Sudo, Yuya, Miyoshi, Toru, Ozaki, Masatomo, Kimura, Yuta, Takagi, Wataru, Ugawa, Satoko, Okada, Tomoaki, Nosaka, Kazumasa, and Doi, Masayuki

Abstract

Myocarditis is an adverse event associated with coronavirus disease 2019 (COVID-19) mRNA vaccination. A 50-year-old man presented with dyspnea and resting chest pain after receiving the second dose of the COVID-19 mRNA vaccine and developed cardiogenic shock. Fulminant myocarditis was diagnosed by endomyocardial biopsy and treated with intravenous corticosteroids.

Published
2022

18. Secular Decreasing Trend in Plasma Eicosapentaenoic and Docosahexaenoic Acids among Patients with Acute Coronary Syndrome from 2011 to 2019: A Single Center Descriptive Study

Author

Okada, Tomoaki, Miyoshi, Toru, Doi, Masayuki, Seiyama, Kosuke, Takagi, Wataru, Sogo, Masahiro, Nosaka, Kazumasa, Takahashi, Masahiko, Okawa, Keisuke, Ito, Hiroshi, Okada, Tomoaki, Miyoshi, Toru, Doi, Masayuki, Seiyama, Kosuke, Takagi, Wataru, Sogo, Masahiro, Nosaka, Kazumasa, Takahashi, Masahiko, Okawa, Keisuke, and Ito, Hiroshi

Abstract

Despite intensive lipid-lowering interventions, patients treated with statins develop atherosclerotic cardiovascular disease (ASCVD), and these patients have an increased risk of developing recurrent cardiovascular events during follow-up. Therefore, there is a need to focus on the residual risks in patients in statin therapy to further reduce ASCVD. The aim of this study was to retrospectively investigate the 10-year trend (2011-2019) regarding changes in polyunsaturated fatty acids (PUFAs) in patients with acute coronary syndrome (ACS) in a single center. We included 686 men and 203 women with ACS admitted to Kagawa Prefectural Central Hospital. Plasma PUFAs, including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (AA), and dihomo-gamma-linolenic acid (DGLA), were measured at admission for suspected ACS. A secular decreasing trend in the levels of EPA and DHA and the EPA/AA ratio, but not of AA and DGLA, was observed. The analyses based on age (>70 or <70 years) and sex showed that the decreasing trend in the levels of EPA and DHA did not depend on age and remained significant only in men. Further studies are needed to obtain robust evidence to justify that the administration of n-3 PUFA contributes to the secondary prevention of ACS.

Published
2021

21. Secular Decreasing Trend in Plasma Eicosapentaenoic and Docosahexaenoic Acids among Patients with Acute Coronary Syndrome from 2011 to 2019: A Single Center Descriptive Study

Author

Okada, Tomoaki, primary, Miyoshi, Toru, additional, Doi, Masayuki, additional, Seiyama, Kosuke, additional, Takagi, Wataru, additional, Sogo, Masahiro, additional, Nosaka, Kazumasa, additional, Takahashi, Masahiko, additional, Okawa, Keisuke, additional, and Ito, Hiroshi, additional

Published
2021
Full Text
View/download PDF

23. Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectoris

Author

Iwamoto Mutsumi, Miyoshi Toru, Doi Masayuki, Takeda Ko, Kajiya Masahito, Nosaka Kazumasa, Nakayama Rie, Hirohata Satoshi, Usui Shinichi, Kusachi Shozo, Sakane Kosuke, Nakamura Kazuhfumi, and Ito Hiroshi

Subjects
Adipocyte, Fatty acid-binding protein, Renal dysfunction, Coronary artery disease, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Background Chronic kidney disease (CKD) is associated with cardiovascular events. Adipocyte fatty acid-binding protein (A-FABP) plays an important role in atherosclerosis. We investigated whether plasma A-FABP is involved in renal function in patients with stable angina pectoris. Methods A total of 221 patients with significant coronary artery stenosis were enrolled after coronary angiography. CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2. The severity of coronary stenosis was assessed using a modified Gensini score and coronary angiography. Serum A-FABP levels were determined by enzyme-linked immunosorbent assay. Results Serum A-FABP levels were significantly correlated with both eGFR (r = -0.41, p < 0.01) and the severity of coronary artery stenosis (r = 0.16, p = 0.02), and these relationships remained significant after adjusting for confounding factors. The prevalence of CKD and multi-vessel disease was significantly higher among patients with serum A-FABP levels above the median value of 20.3 ng/ml than among patients with serum A-FABP levels below the median value (57% vs. 27%, p < 0.01 and 64% vs. 48%, p = 0.02, respectively). Multivariate analysis revealed that the presence of three-vessel disease in comparison with single-vessel disease was independently associated with the higher A-FABP (per doubling) (odds ratio; 2.26, 95% confidential interval; 1.28-3.98, p < 0.01) and tended to be associated with the lower eGFR (p = 0.06). Conclusion Serum A-FABP may have a significant role in the interplay between renal dysfunction and coronary atherosclerosis.

Published
2012
Full Text
View/download PDF

25. Cardio-ankle vascular index is a predictor of all-cause mortality and cardiovascular events in patients with stable coronary artery disease after successful revascularization

Author

Sudo, Yuya, primary, Miyoshi, Toru, additional, Hara, Shohei, additional, Matsuo, Naoaki, additional, Sogo, Masahiro, additional, Ugawa, Satoko, additional, Okada, Tomoaki, additional, Nosaka, Kazumasa, additional, Takahashi, Masahiro, additional, Okawa, Keisuke, additional, Sakane, Kosuke, additional, and Doi, Masayuki, additional

Published
2017
Full Text
View/download PDF

29. Circulating adipocyte fatty acid-binding protein is a predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention.

Author

Wataru Takagi, Toru Miyoshi, Masayuki Doi, Keisuke Okawa, Kazumasa Nosaka, Tomoyuki Nishibe, Naoaki Matsuo, Satoshi Hirohata, Hiroshi Ito, Takagi, Wataru, Miyoshi, Toru, Doi, Masayuki, Okawa, Keisuke, Nosaka, Kazumasa, Nishibe, Tomoyuki, Matsuo, Naoaki, Hirohata, Satoshi, and Ito, Hiroshi

Subjects
CORONARY disease, FATTY acid-binding proteins, FAT cells, PERCUTANEOUS coronary intervention, HEART failure, CARDIOVASCULAR disease related mortality, CARDIOVASCULAR disease diagnosis, ANGINA pectoris, CARDIOVASCULAR system, CARDIOVASCULAR diseases, CARRIER proteins, CLINICAL trials, COMPARATIVE studies, LONGITUDINAL method, RESEARCH methodology, MEDICAL care, MEDICAL cooperation, RESEARCH, EVALUATION research, SURGICAL complications, PREDICTIVE tests, RETROSPECTIVE studies, DIAGNOSIS
Abstract

Background: Adipocyte fatty acid-binding protein (A-FABP) is expressed in both adipocytes and macrophages. Recent studies have shown that A-FABP is secreted by adipocytes and that the A-FABP concentration is associated with obesity, insulin resistance, and atherosclerosis. We have reported that the coronary atherosclerotic burden is associated with the serum A-FABP concentration. In the present study, we investigated whether the serum A-FABP concentration is associated with prognosis in patients with stable angina pectoris who have undergone percutaneous coronary intervention (PCI).Methods: This was a prospective single-center trial. In total, 130 patients with stable angina pectoris undergoing their first PCI were enrolled from August 2008 to July 2010 at Kagawa Prefectural Central Hospital. The primary endpoints were cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, revascularization, and hospitalization for heart failure.Results: During the follow-up (median, 50 months; interquartile range, 23-66 months), 49 cardiovascular events occurred. Kaplan-Meier analysis showed that the cumulative incidence of the primary endpoints in the high A-FABP group (median A-FABP concentration of ≥ 18.6 ng/ml) was greater than that in the low A-FABP group. Cox analysis showed that the A-FABP concentration was an independent predictor of cardiovascular events adjusted for age and the presence of multi-vessel disease (hazard ratio, 1.03; 95% confidence interval, 1.01-1.04; p = 0.01).Conclusion: The serum A-FABP concentration is associated with prognosis in patients with stable angina undergoing PCI, suggesting that the serum A-FABP concentration could be useful for risk assessment of secondary prevention.Trial Registration: UMIN Clinical Trials Registry UMIN000029283 (registration date: September 25, 2017), retrospectively registered. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

30. Low serum level of secreted frizzled-related protein 5, an anti-inflammatory adipokine, is associated with coronary artery disease

Author

Miyoshi, Toru, primary, Doi, Masayuki, additional, Usui, Shinichi, additional, Iwamoto, Mutsumi, additional, Kajiya, Masahito, additional, Takeda, Ko, additional, Nosaka, Kazumasa, additional, Nakayama, Rie, additional, Okawa, Keisuke, additional, Takagi, Wataru, additional, Nakamura, Kazufumi, additional, Hirohata, Satoshi, additional, and Ito, Hiroshi, additional

Published
2014
Full Text
View/download PDF

32. Serum adipocyte fatty acid-binding protein is independently associated with complex coronary lesions in patients with stable coronary artery disease

Author

Kajiya, Masahito, primary, Miyoshi, Toru, additional, Doi, Masayuki, additional, Usui, Shinichi, additional, Iwamoto, Mutsumi, additional, Takeda, Ko, additional, Nosaka, Kazumasa, additional, Nakayama, Rie, additional, Hirohata, Satoshi, additional, Kusachi, Shozo, additional, Nakamura, Kazufumi, additional, and Ito, Hiroshi, additional

Published
2012
Full Text
View/download PDF

33. AS-062 Comparison of Coronary Plaque Characterization by Spectral Radiofrequency of Intravascular Ultrasound Signals (VH-IVUS and i-MAP)

Author

Hirohata, Atsushi, primary, Yamamoto, Keizo, additional, Imai, Yoshihiro, additional, Senoh, Keitaro, additional, Hirose, Eiki, additional, Kobayashi, Yuhei, additional, Takafuji, Hiroya, additional, Sano, Fumihiko, additional, Ohara, Minako, additional, Ohkawa, Keisuke, additional, Toyama, Yuko, additional, Nosaka, Kazumasa, additional, Yoshida, Junji, additional, Iino, Yuzuru, additional, and Ohe, Tohru, additional

Published
2011
Full Text
View/download PDF

34. AS-200: Risk Factors for Coronary Plaque Progression in Patients with Asians: A Serial Volumetric Intravascular Ultrasound Analysis

Author

Hirohata, Atsushi, primary, Yamamoto, Keizo, additional, Imai, Yoshihiro, additional, Hirose, Eiki, additional, Ohkawa, Keisuke, additional, Ohara, Minako, additional, Toyama, Yuko, additional, Miyamoto, Yoshinori, additional, Nosaka, Kazumasa, additional, Sehoh, Keitaro, additional, Sato, Shinji, additional, Yoshida, Junji, additional, and Ohe, Toru, additional

Published
2010
Full Text
View/download PDF

35. AS-238: Efficacy and Complications of a Vascular Closure Device (Angioseal STS Plus): Experience from 807 Interventions

Author

Hirohata, Atsushi, primary, Yamamoto, Keizo, additional, Imai, Yoshihiro, additional, Hirose, Eiki, additional, Ohkawa, Keisuke, additional, Ohara, Minako, additional, Toyama, Yuko, additional, Miyamoto, Yoshinori, additional, Nosaka, Kazumasa, additional, Sehoh, Keitaro, additional, Sato, Shinji, additional, Yoshida, Junji, additional, and Ohe, Toru, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results